Project Number 5U01AG046139-10 Agency/Funding Organization NIA Funding Year 2022 View Full Project Details for A Systems Approach to Targeting Innate Immunity in AD Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 2. Identification and Validation of Novel Targets Category G. Consortia and Public Private Partnerships 2. Public Private Partnership Researcher and Organization Principal Investigator ERTEKIN-TANER, NILUFER Principal Investigator First Name GUOJUN Principal Investigator Last Name BU Awardee Organization MAYO CLINIC JACKSONVILLE Awardee State Florida Contact PI Country United States Project Detail Funding Opportunity Announcement RFA-AG-18-013: Continuation of the AMP-AD Target Discovery and Preclinical Validation Consortium (U01 Clinical Trial Optional) FY Overall Cost $2,421,378 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official PETANCESKA, SUZANA Special Initiative Accelerating Medicines Partnership - Alzheimer's Disease (AMP-AD): Target Discovery and Preclinical Validation Project Related Resources Repository [AMP-AD Knowledge Portal] A System Approach to Targeting Innate Immunity in AD
